Korro Bio Investor Relations Material

Korro Bio Inc. is a biopharmaceutical company engaged in the field of RNA editing to develop new genetic medicines. The company's innovative approach, leveraging the Oligonucleotide Promoted Editing of RNA (OPERA) platform, aims to harness natural processes for making transient, reversible changes to genetic instructions. This technology seeks to offer potential treatments for patients with rare and highly prevalent diseases by overcoming the complexities of earlier gene-editing methods. The company is headquartered in Cambridge, Massachusetts, and its shares are listed on the Nasdaq.